Results 31 to 40 of about 1,535,241 (215)

Myoferlin disturbs redox equilibrium to accelerate gastric cancer migration

open access: yesFrontiers in Oncology, 2022
ObjectiveIn contrast to normal cells, in which reactive oxygen species (ROS) are maintained in redox equilibrium, cancer cells are characterized by ectopic ROS accumulation.
Hailong Shi   +8 more
doaj   +1 more source

Antiviral chemotherapy [PDF]

open access: yesInfection, 1984
After a discussion of the principles of antiviral chemotherapy, treatment and chemoprophylaxis of the following virus infections are reviewed in detail: the various manifestations of herpes simplex virus infections, varicella-zoster, cytomegalovirus infections, Epstein-Barr virus infections, laryngeal papillomas, and influenza A.
openaire   +3 more sources

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study [PDF]

open access: yes, 2008
Summary Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy.
Impact of Neutropenia in Chemotherapy-European Study Group (INC-   +26 more
core   +1 more source

Candidate genes in gastric cancer identified by constructing a weighted gene co-expression network [PDF]

open access: yesPeerJ, 2018
Background Gastric cancer (GC) is one of the most common cancers with high mortality globally. However, the molecular mechanisms of GC are unclear, and the prognosis of GC is poor.
Jian Chen   +5 more
doaj   +2 more sources

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy : systematic review and meta-analysis [PDF]

open access: yes, 2011
Background: Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays.
Akehurst Ron L   +19 more
core   +2 more sources

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial [PDF]

open access: yes, 2013
Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial in early breast cancer, enroled 831 patients in the United Kingdom.
K Walland   +25 more
core   +2 more sources

The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial [PDF]

open access: yes, 2013
Background: Chemotherapy-induced nausea and vomiting remain difficult symptoms to manage in clinical practice. As standard antiemetic drugs do not fully eliminate these symptoms, it is important to explore the adjuvant role of non-pharmacological and ...
Lloyd-Williams, M   +34 more
core   +1 more source

Node-positive breast cancer: Which are the best chemotherapy regimens? [PDF]

open access: yes, 2008
Breast cancer-associated mortality has been significantly reduced since the 1990s, mainly because of early diagnosis and systemic therapeutic interventions.
Bauerfeind, Ingo   +6 more
core   +1 more source

Ceftazidimeavibactam use in children and adolescents [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2021
The increasing number of infections caused by multidrug-resistant gram-negative bacteria in children is a serious problem all over the world. Ceftazidim-avibactam is a promising antimicrobial drug recently approved in Russia for use in pediatric practice.
Stetsiouk О.U.   +3 more
doaj   +1 more source

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. [PDF]

open access: yes, 2010
Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely
Clarkson, Jan E.; id_orcid   +51 more
core   +1 more source

Home - About - Disclaimer - Privacy